These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21286272)

  • 1. Cost shifting and timeliness of drug formulary decisions in atlantic Canada.
    Scobie AC; Mackinnon NJ
    Healthc Policy; 2010 Feb; 5(3):100-14. PubMed ID: 21286272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does variation among provincial drug formulary antimicrobial listings in Canada influence prescribing rates?
    Glass-Kaastra SK; Finley R; Hutchinson J; Patrick DM; Weiss K; Conly J
    PLoS One; 2014; 9(9):e107515. PubMed ID: 25203557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breadth, Depth and Agreement among Provincial Formularies in Canada.
    Morgan S; Hanley G; Raymond C; Blais R
    Healthc Policy; 2009 May; 4(4):e162-84. PubMed ID: 20436800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers.
    Foroutan N; Tarride JE; Xie F; Mills F; Levine M
    Pharmacoecon Open; 2019 Dec; 3(4):437-451. PubMed ID: 31041614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions: an exploratory study.
    Allen N; Walker SR; Liberti L; Sehgal C; Salek MS
    CMAJ Open; 2016; 4(4):E674-E678. PubMed ID: 28018881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis.
    Lexchin J
    BMJ Open; 2017 Oct; 7(10):e018372. PubMed ID: 29061631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand.
    McCormick JI; Berescu LD; Tadros N
    Orphanet J Rare Dis; 2018 Jan; 13(1):27. PubMed ID: 29382371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inter-provincial variation in government drug formularies.
    Grégoire JP; MacNeil P; Skilton K; Moisan J; Menon D; Jacobs P; McKenzie E; Ferguson B
    Can J Public Health; 2001; 92(4):307-12. PubMed ID: 11962119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans.
    Salek S; Lussier Hoskyn S; Johns JR; Allen N; Sehgal C
    Front Pharmacol; 2019; 10():196. PubMed ID: 30983993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of product listing agreements by Canadian provincial drug benefit plans.
    Morgan SG; Friesen MK; Thomson PA; Daw JR
    Healthc Policy; 2013 May; 8(4):45-55. PubMed ID: 23968637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of the introduction of a formulary into a large Canadian private drug plan: an interrupted time-series analysis.
    Cassels A; Law MR
    CMAJ Open; 2019; 7(3):E472-E477. PubMed ID: 31320330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Exploratory Analysis of Predictors of Concordance between Canadian Common Drug Review Reimbursement Recommendations and the Subsequent Decisions by Ontario, British Columbia and Alberta.
    Zoratti MJ; Xie F; Thorlund K; Allen N; Levine M
    Healthc Policy; 2020 Feb; 15(3):90-101. PubMed ID: 32176613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the pan-Canadian Oncology Drug Review on provincial concordance with respect to cancer drug funding decisions and time to funding.
    Srikanthan A; Mai H; Penner N; Amir E; Laupacis A; Sabharwal M; Chan KKW
    Curr Oncol; 2017 Oct; 24(5):295-301. PubMed ID: 29089796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Provincial drug plan officials' views of the Canadian drug safety system.
    Lexchin J; Wiktorowicz M; Moscou K; Eggertson L
    J Health Polit Policy Law; 2013 Jun; 38(3):545-71. PubMed ID: 23418364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications.
    Salek SM; Lussier Hoskyn S; Johns J; Allen N; Sehgal C
    Front Pharmacol; 2018; 9():1578. PubMed ID: 30833899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The timing of drug funding announcements relative to elections: a case study involving dementia medications.
    Gill SS; Gupta N; Bell CM; Rochon PA; Austin PC; Laupacis A
    PLoS One; 2013; 8(2):e56921. PubMed ID: 23460820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: "cost shifting and timeliness of drug formulary recommendations in atlantic canada," healthcare policy, vol. 5, no. 3, 2010.
    Healthc Policy; 2010 Aug; 6(1):11-4. PubMed ID: 21804834
    [No Abstract]   [Full Text] [Related]  

  • 18. Medicine reimbursement recommendations in Canada, Australia, and Scotland.
    Lexchin J; Mintzes B
    Am J Manag Care; 2008 Sep; 14(9):581-8. PubMed ID: 18778173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Jun; 27(2):e58-e67. PubMed ID: 32543163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement.
    West R; Borden EK; Collet JP; Rawson NS; Tonks RS
    Can J Public Health; 2002; 93(6):421-5. PubMed ID: 12448863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.